Patents Examined by Larry Helms
-
Patent number: 8445000Abstract: The present invention relates to immunogenic compositions, comprising polypeptides isolated from Staphylococcus epidermidis. The invention also relates to polynucleotides encoding Staphylococcus epidermidis polypeptides and their use in immunogenic compostions. In addition, the invention relates to methods of inducing an immune response in mammals against Staphylococcus epidermidis and Staphylococcus aureus using immunogenic compostions of the Staphylococcus epidermidis polypeptides and polynucleotides. The invention also relates to methods for detecting Staphylococcus epidermidis in a biological sample.Type: GrantFiled: October 19, 2005Date of Patent: May 21, 2013Assignee: Wyeth LLCInventors: Bret Richard Sellman, Steven Morris Baker
-
Patent number: 8435951Abstract: The present invention provides a method of treating a cancer using a neurotoxin, preferably Botulinum toxin (“BTX”). The application of a neurotoxin around a cancer acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze cancer cells through efferent channels leaving the cancer vicinity to distant sites. Also, the application of the toxin at sites distant from the cancer enhances cellular and humoral immunologic functions which further contributes to cancer cell death and spread. Following administration of botulinum toxin around and distant to a cancer, it is noticed that local, regional, and distant spread is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other disease that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV.Type: GrantFiled: March 17, 2010Date of Patent: May 7, 2013Assignee: Toxcure, Inc.Inventor: Christopher Shaari
-
Patent number: 7862817Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.Type: GrantFiled: January 27, 2005Date of Patent: January 4, 2011Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
-
Patent number: 7807392Abstract: The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung cancer (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as targets for screening agents that modulates the LCAT activities. Further the present invention provides methods for treating diseases associated with lung.Type: GrantFiled: September 28, 2007Date of Patent: October 5, 2010Assignee: Celera CorporationInventors: Bruno Domon, Elizabeth Joseloff, Aiqun Li, Tao He
-
Patent number: 7445802Abstract: Conjugates of the enzyme alliinase with a protein carrier that targets the alliinase to specific cells are used in combination with alliin to produce allicin at a desired target site. The enzyme converts alliin to allicin at the target site to kill cancer cells or pathogens.Type: GrantFiled: December 26, 2001Date of Patent: November 4, 2008Assignee: Yeda Research and Development Co. LtdInventors: Aharon Rabinkov, Talia Miron, David Mirelman, Meir Wilchek
-
Patent number: 7439031Abstract: The present invention provides methods of identifying and/or detecting anti-cancer agents. The present invention provides methods of identifying and/or detecting compounds that can activate PARP and/or induce necrosis. The present invention also provides for methods of treating cancer in an individual. The present invention also provides kits for identifying and/or detecting anti-cancer agents.Type: GrantFiled: December 15, 2004Date of Patent: October 21, 2008Assignee: The Trustees of the University of PennsylvaniaInventors: Craig B. Thompson, Wei-Xing Zong
-
Patent number: 7431926Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.Type: GrantFiled: June 14, 2004Date of Patent: October 7, 2008Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Curtis C. Harris, Makoto Nagashima
-
Patent number: 7429382Abstract: The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a CA 125/O772P-related disorder. In particular, the present invention provides methods of preventing, managing, treating, or ameliorating one or more symptoms associated with a cell proliferative disorder, such as cancer, e.g., ovarian cancer. The present invention still further provides methods for diagnosing a CA 125/O772P-related disorder or predisposition to developing such a disorder, as well as methods for identifying antibodies, and antigen-binding fragments of antibodies, that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides.Type: GrantFiled: October 15, 2003Date of Patent: September 30, 2008Assignee: Corixa CorporationInventors: Earl F. Albone, Daniel A. Soltis
-
Patent number: 7425217Abstract: Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.Type: GrantFiled: May 24, 2003Date of Patent: September 16, 2008Inventors: Nathan C. Maier, Amiel G. Jarstfer, James C. Peacock, III
-
Patent number: 7425612Abstract: The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease.Type: GrantFiled: August 10, 2004Date of Patent: September 16, 2008Assignee: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Yoichi Furukawa, Hideaki Tahara, Takuya Tsunoda
-
Patent number: 7419792Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to such diagnosis and treatment which revolves around the ability of the 5LAC-23 monoclonal antibody (or antigenic binding fragments derived therefrom) to bind with the Laminin Receptor 1 Precursor Protein 37LRP; and most particularly to diagnosis and treatment of Hepatocellular Carcinoma by various means which rely upon direct binding of 5LAC-23 with the particular antigenic moiety specifically recognized thereby and generally overexpressed in Hepatocellular carcinoma cells. The invention additionally relates to the treatment of such cells with conjugated moieties effective to aid in differentiation, treatment and diagnostic imaging thereof.Type: GrantFiled: March 14, 2005Date of Patent: September 2, 2008Assignees: Arius Research Inc., Oxford Biomedica UK Ltd.Inventors: David S. F. Young, Susan E. Hahn, Fortunata McConkey, Michelle Kelleher, Andrea Warner
-
Patent number: 7419659Abstract: The present invention relates to a method of production of antibodies wherein the heavy and light chains of a particular antibody molecule are encoded by the DNA present in a dicistronic message in which the two cistrons are linked by an optimised intergenic sequence.Type: GrantFiled: December 5, 2002Date of Patent: September 2, 2008Assignee: UCB Pharma S.A.Inventor: Andrew George Popplewell
-
Patent number: 7410644Abstract: Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen.Type: GrantFiled: July 17, 2002Date of Patent: August 12, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey Schlom, Dennis L. Panicali, Linda R. Gritz, Gail P. Mazzara
-
Patent number: 7407745Abstract: By analyzing the mechanism for inducing a histone deacetylase inhibitor (Trichostatin A)-mediated expression of cyclin-CDK inhibitory factor having a proliferation suppressing effect (tumor-suppressing effect), it was revealed that the binding of Sp3 to the Sp1 binding sequence within a promoter is important in the expression of the above factor. Thus, a novel antitumor agent can be developed by screening a pharmaceutical agent capable of elevating Sp3 activity.Type: GrantFiled: March 23, 2000Date of Patent: August 5, 2008Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshihiro Sowa, Tetsuro Orita
-
Patent number: 7402298Abstract: The invention provides a monoclonal antibody, a fragment thereof, or a molecular complex thereof that binds to an extracellular domain of an EphA2 receptor molecule, wherein binding of the monoclonal antibody or fragment thereof to the EphA2 receptor molecule present in the membrane of a cancer cell favorably alters activity of the EphA2 receptor molecule. The invention further relates to methods of making and using the monoclonal antibodies, fragments, and molecular complexes regarding the same. The monoclonal antibodies of the present invention target the extracellular domain of EphA2 and operate to redirect the function of EphA2 to selectively block the growth and invasiveness of metastatic cells. The invention thus makes possible therapeutic strategies that optimally target metastatic cells while preventing collateral damage to normal tissues.Type: GrantFiled: December 2, 2004Date of Patent: July 22, 2008Assignees: Purdue Research Foundation, SmithKline Beecham CorporationInventors: Michael Scott Kinch, Kelly Carles-Kinch, Katherine E Kilpatrick
-
Patent number: 7399594Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.Type: GrantFiled: December 3, 2002Date of Patent: July 15, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Russell P. Rother, Dayang Wu
-
Patent number: 7393648Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.Type: GrantFiled: June 3, 2003Date of Patent: July 1, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Russell Rother, Dayang Wu
-
Patent number: 7384909Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: GrantFiled: August 15, 2003Date of Patent: June 10, 2008Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, M. Melina Soares, Jin He
-
Patent number: 7375199Abstract: The present invention is related to a DNA comprising a nucleotide sequence encoding a polypeptide represented by SEQ ID NO:1 or SEQ ID NO:2. The DNA according to the present invention is highly expressed in prostatic adenocarcinoma and ovarian carcinoma, and is a cancer-associated gene, so that it is possible to inhibit cancer by blocking the binding of the present protein to its ligand. Accordingly, the present antibody is used not only in the detection of the present protein, but also as an agent for the treatment or prevention of cancers such as prostatic adenocarcinoma and ovarian carcinoma.Type: GrantFiled: December 21, 2001Date of Patent: May 20, 2008Assignees: Kazusa DNA Research Institute Foundation, Chugai Seiy Aku Kabushiki KaishaInventors: Osamu Ohara, Takahiro Nagase, Daisuke Nakajima, Shin-ichi Funahashi
-
Patent number: 7115727Abstract: A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization.Type: GrantFiled: May 9, 2003Date of Patent: October 3, 2006Assignee: Agensys, Inc.Inventors: Mary Faris, Pia M. Challita-Eid, Aya Jakobovits, Arthur B. Raitano, Wangmao Ge